Physician profile
Wilburn E George
NPI 1902862519
$1,636.31
in general payments reported to CMS, 2019-2025
16 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $73.58 · 2021: $100 · 2022: $481 · 2023: $411 · 2024: $344 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $548.95 | 2022-2025 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $211.22 | 2020-2024 | |
| Pfizer INC. | $165.86 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $158.57 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $121.22 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $88.27 | 2020-2025 | Ozempic, Rybelsus |
| Heartflow, INC. | $81.53 | 2023-2024 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.25 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $55.80 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Vital Connect, INC | $42.66 | 2022 | |
| Qorumpartners | $24.93 | 2022 | |
| Scpharmaceuticals INC. | $20.66 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.63 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $15.02 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $13.17 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilburn George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.